Nearly 580 participants will be enrolled at sites across Europe, Asia, South America, and North America.

Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced ...

The first patient has been dosed in the randomization phase of the DESTINY-Ovarian01 phase 3 trial evaluating Enhertu in combination with ...

Philadelphia, PA, USA, December 9, 2025, First Patient Enrolled in GOG-3133/ FRAmework-01 Phase 3 Study Evaluating Sofetabart ...

Use of anti-VEGF therapies varies by both U.S. Census region and patient population, according to research presented at the ...

EO2401 in vivo immune therapy + nivolumab +/- bevacizumab shows survival benefit in first recurrent glioblastomaData presented at 2025 SNO ...

The treatment strategy may involve a combination of surgery, radiation therapy, immunotherapy, and chemotherapy, each aimed at slowing disease progression and, in many cases, temporarily reducing the ...

In a post hoc analysis of the FIRE-3 trial, researchers evaluated the impact of sex on the efficacy and safety of first-line treatment with FOLFIRI plus cetuximab for patients with RAS/BRAF wild-type ...

Mirvetuximab soravtansine (MIRV; Elahere; AbbVie) demonstrated significant efficacy and an acceptable safety profile in the treatment of recurrent ovarian cancer, showing particular promise in ...

A live webcast of the fireside chat will be accessible on the Events page in the Investors section of the Company’s website ( outlooktherapeutics.com ). The webcast replay will be archived for 90 days ...

Background and Purpose: The lesional phenotype of human brain arteriovenous malformation (bAVM) includes increased VEGF expression compared to normal brain. We developed an adult mouse model of bAVM ...

High CD8-positive T cell infiltration is linked to shorter PFS in epithelial ovarian cancer patients treated with bevacizumab. The IMM subtype, which usually has a favorable prognosis, showed worse ...